Pure Global
NCT06041789

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism and Fracture Risk Factors Among Older Adults With Mild to Moderate Alzheimer's Disease
Duke University·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Osteoporosis
Drug/Device/Intervention
Donepezil
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Duke University
Location
Durham, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Dec 04, 2023
End date
Mar 01, 2025
Enrollment
45 participants
Primary outcome

Change in bone mineral density, as measured by dual x-ray absorptiometry (DXA)

Summary

People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have
 shown that those taking donepezil have a lower rate of bone fractures, but the reasons for
 this are unknown. The purpose of this study is to measure the effect of donepezil treatment
 on bone metabolism factors including bone mineral density, bone turnover markers, and bone
 quality.
 
 Participants in this study will have a bone density test and have blood samples collected at
 the baseline study visit. Participants will then be randomly assigned to donepezil or
 matching placebo to be taken daily by mouth for 12 months. Blood samples will be collected at
 6 and 12 months. A repeat bone density test will be performed at 12 months. Participants will
 also complete questionnaires at each study visit.

ICD-10 classifications
Osteoporosis, unspecifiedOther osteoporosisIdiopathic osteoporosisOsteoporosis in diseases classified elsewherePostmenopausal osteoporosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06041789
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06041789 through Pure Global AI's free database. This Phase 2 trial is sponsored by Duke University and is currently Not yet recruiting. The study focuses on Osteoporosis. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.